A systematic review of 15 studies found CBD attacked pancreatic cancer cells through multiple pathways and enhanced chemotherapy effectiveness, but clinical evidence remains absent.
Oncology researchers, scientists studying cannabinoid anti-cancer mechanisms, and clinicians following emerging pancreatic cancer therapies.
CBD enhanced gemcitabine chemotherapy effectiveness in preclinical models
What the researchers found
CBD exhibited antitumor properties through ER stress and apoptosis (via CerS1), GPR55/MAPK inhibition, immune modulation, and chemosensitization to gemcitabine. Combination therapies with other cannabinoids or chemotherapeutics enhanced outcomes in preclinical models.
Why it matters
Pancreatic cancer has the worst survival rate of any common cancer and desperately needs new treatment approaches. CBD's ability to attack tumor cells through multiple pathways and sensitize them to chemotherapy warrants further investigation.
The numbers in context
15 studies met inclusion criteria. CBD pathways identified: CerS1-mediated ER stress, GPR55/MAPK inhibition, immune modulation, gemcitabine chemosensitization. Combination therapies outperformed CBD alone in preclinical models.
How the study worked
Systematic review of PubMed, Scopus, Web of Science, EMBASE, and Google Scholar (2006-2025), including 15 studies examining CBD's effects on pancreatic ductal adenocarcinoma in vitro, in vivo, and clinical contexts.
What this study cannot tell us
Almost entirely preclinical evidence. No controlled clinical trials exist. CBD doses used in lab studies may not be achievable in patients. Publication bias may favor positive preclinical results.
How to read the evidence
Systematic review is thorough but the underlying evidence is almost entirely preclinical. No clinical efficacy data exists for this indication.
When this study was published
Published in 2025, literature 2006-2025.
The bigger picture
Pancreatic cancer's treatment resistance stems partly from its ability to evade single-pathway therapies. CBD's multi-target approach, particularly its chemosensitization effects, could potentially complement existing treatments if validated clinically.
Questions still open
- Can therapeutic CBD concentrations be achieved at the tumor site? Would CBD improve gemcitabine outcomes in a clinical trial?
Common questions
Could CBD help treat pancreatic cancer?
How does CBD fight cancer cells in the lab?
Read the original research
Cannabidiol in pancreatic ductal adenocarcinoma: preclinical evidence, molecular mechanisms, and translational challenges.
Cancer cell international, 25(1), 415
Citation
Esmaeli, Mojtaba; Dehghanpour Dehabadi, Maryam; Khaleghi, Ali Asghar. (2025). Cannabidiol in pancreatic ductal adenocarcinoma: preclinical evidence, molecular mechanisms, and translational challenges.. Cancer cell international, 25(1), 415. https://doi.org/10.1186/s12935-025-04062-9
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk